Prenetics Reinforces Strategic Focus on IM8, Divests Europa Business For Up to $13 Million
Rhea-AI Summary
Prenetics (NASDAQ: PRE) completed an all-stock sale of its 3PL business Europa on Jan 1, 2026, a divestiture valued at up to $13 million subject to performance milestones. The move is part of a portfolio optimization that followed the $72 million sale of ACT Genomics in October 2025 and aims to concentrate resources on the IM8 health and longevity brand.
The company reported a strong balance sheet with over $70 million cash, 510 BTC, zero debt and approximately $118 million total liquidity. Prenetics projects IM8 revenue of $180–$200 million in 2026 and expects operating-margin improvement beginning in Q2 2026 after eliminating Europa’s ~$6 million operating loss in FY2025.
Positive
- IM8 revenue guidance $180–$200M for 2026
- Total liquidity ≈ $118M (>$70M cash + 510 BTC + zero debt)
- ACT Genomics sale $72M closed Oct 2025
- Europa sale completed Jan 1, 2026; up to $13M all-stock
Negative
- Europa operating loss ≈ $6M in FY2025
- Europa consideration contingent on performance milestones up to $13M
Key Figures
Market Reality Check
Peers on Argus
PRE gained 0.44% while peers were mixed: BNR up 23.02%, others like MDXH and BDSX fell 4.89% and 3.71%, suggesting a stock-specific reaction.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 30 | Capital allocation shift | Positive | -3.3% | Ended Bitcoin purchases and reallocated capital exclusively toward IM8. |
| Dec 23 | Warrant exchange | Positive | -6.9% | Voluntary warrant exchange to simplify capital structure and reduce dilution. |
| Nov 25 | Conference participation | Neutral | +8.6% | Announced participation in December investor conferences and presentations. |
| Nov 24 | Insider share purchases | Positive | +11.2% | Executives made open-market share purchases totaling about $1.45M. |
| Nov 14 | Analyst rating update | Positive | -9.4% | Overweight rating and $31 target following strong IM8 growth metrics. |
Recent history shows several positive or strategic updates followed by mixed to negative price reactions, indicating a tendency for the stock to sometimes sell off or underreact to constructive news.
Over the past months, Prenetics has repeatedly emphasized shifting capital and strategy toward IM8. A December 2025-12-30 update ended Bitcoin purchases while keeping 510 BTC and highlighted projected $180–$200M FY2026 IM8 revenue. Prior items included a warrant exchange to streamline dilution, insider share purchases in November, and an Overweight rating with a $31 target after strong 3Q25 IM8 growth. Today’s Europa divestiture continues this streamlining and IM8-focused trajectory.
Market Pulse Summary
This announcement continues Prenetics’ portfolio streamlining, divesting Europa for up to $13 million after a prior $72 million ACT Genomics sale, and sharpening focus on IM8. The company highlights over $70 million in cash, 510 BTC, and approximately $118 million in total liquidity with zero debt. Investors may track delivery on projected $180–$200M IM8 2026 revenue, margin improvement from removing about $6 million in Europa losses, and any monetization of the $70 million-valued Insighta stake.
Key Terms
3PL technical
BTC financial
AI-generated analysis. Not financial advice.
Company Continues Portfolio Optimization on the Heels of Successful
Company Maintains Strong Balance Sheet with over
CHARLOTTE, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced that it has completed the sale of its 3PL distribution business operated by its subsidiary, Europa Sports Partners. The all-stock transaction is valued at up to
This strategic divestiture allows Prenetics to further sharpen its focus on IM8, one of the world’s fastest-growing supplement brands, positioning the Company to drive long-term shareholder value by scaling IM8 globally. As IM8 continues to scale rapidly across multiple international markets, Europa’s operating model became increasingly unaligned with the Company’s long-term logistics and global expansion requirements.
The sale of the Europa business represents the second major divestiture in Prenetics' strategic portfolio optimization initiative, following the successful
The sale was completed on January 1, 2026, and therefore has no impact on the Company’s revenue or financial results for the fiscal year 2025. The Company's financial performance for fiscal year 2025 will include the full-year contribution from the Europa business.
Danny Yeung, Chief Executive Officer and Co-Founder of Prenetics, commented, “The sale of our Europa business marks another important milestone in our strategic transformation towards a sole focus on IM8. We originally acquired Europa ahead of the launch of IM8 to support our early logistics and 3PL requirements. However, the tremendous growth of IM8 has outpaced Europa’s operating scale, making divestment of the asset the most efficient path forward.
Given our strong balance sheet, we deliberately structured this transaction as an all-stock deal, reflecting our conviction in the upside potential of the acquiring company while achieving our primary objective of business simplification. The divestiture of the Europa business is expected to improve Prenetics' operating margins beginning in Q2 2026, as the Company will no longer incur operating losses from this non-core business, which amounted to approximately
Looking ahead in 2026, IM8 has emerged as a globally recognized and rapidly scaling brand, with strong momentum across key international markets and a growing ecosystem of partners, products, and channels. Now with our clear strategic focus on IM8, we are excited about the opportunities ahead and believe we are well positioned to pursue several meaningful initiatives that could further enhance long-term value.”
Continued Strategic Review
As previously stated, Prenetics will continue its comprehensive strategic review of remaining key non-core assets, including its
About Prenetics
Prenetics (NASDAQ: PRE) is a leading health sciences company redefining the future of health and longevity through IM8 — its flagship consumer brand co-founded with David Beckham and championed by World No. 1 and four-time Grand Slam winner Aryna Sabalenka. IM8 has achieved the fastest growth trajectory in supplement industry history, reaching
About IM8
IM8 is the pinnacle of premium core nutrition, born from a collaboration between David Beckham as a co-founding partner, and an elite team of scientists spanning medical professionals, academia and space science. Combining cutting-edge science with nature’s most potent ingredients, IM8 delivers a holistic, science-backed approach to health, empowering you to live your most vibrant life. IM8’s flagship product, Daily Ultimate Essentials is an all-in-one powder supplement engineered to replace 16 different supplements in a delicious drink and is NSF Certified for Sport, non-GMO, vegan, free from common allergens, and contains no artificial flavors, colors or sweeteners. IM8 is a subsidiary of Prenetics (NASDAQ: PRE), a leading global health sciences company dedicated to advancing consumer health. To learn more about IM8, please visit www.IM8health.com.
Investor Relations Contact
investors@prenetics.com
PRE@mzgroup.us
Angela Cheung
Investor Relations / Corporate Finance
angela.hm.cheung@prenetics.com
Forward-Looking Statements
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s goals, targets, projections, outlooks, beliefs, expectations, strategy, plans, objectives of management for future operations of the Company, and growth opportunities are forward-looking statements. Our guidance reflects management’s current estimates and assumptions as of the date of this release, is subject to significant risks and uncertainties, and is not a guarantee of future performance. Actual results may differ materially. In some cases, forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to,” “guidance,” “outlook,” “forecast,” or other similar expressions. Forward-looking statements are based upon estimates and forecasts and reflect the views, assumptions, expectations, and opinions of the Company, which involve inherent risks and uncertainties, and therefore they should not be relied upon as being necessarily indicative of future results. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to: future alpha-generating activities involving the Company’s Bitcoin holdings could expose it to additional risks; the Company’s purchase of Bitcoin subjects it to risks related to extreme volatility and speculative nature of Bitcoin; the Company may not be able to maintain and enhance its IM8 business and brand if it suffers negative publicity or fails to maintain a strong base of engaged customers and content creators, or otherwise fails to meet customers’ expectations; the Company’s ability to further develop and grow its business, including new products and services; and its ability to identify and execute on M&A opportunities. In addition to the foregoing factors, you should also carefully consider the other risks and uncertainties described in the “Risk Factors” section of the Company’s most recent registration statement and the prospectus therein, and the other documents filed by the Company from time to time with the U.S. Securities and Exchange Commission. Unless otherwise specified, all information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.
FAQ
What did Prenetics announce about the Europa business on Jan 1, 2026 (PRE)?
How much liquidity does Prenetics (PRE) report after the Europa divestiture?
What revenue does Prenetics project for IM8 in 2026 (PRE)?
When will Prenetics expect margin improvement from the Europa sale (PRE)?
How large were Europa’s operating losses included in FY2025 for Prenetics (PRE)?
How does the Europa sale fit Prenetics’ broader strategy (PRE)?
